62 results about "Antigen delivery" patented technology

The invention discloses an attenuated salmonella typhimurium EN-VNP (Enhanced Natriuretic Peptide) strain as well as a preparation method and application of the attenuated salmonella typhimurium EN-VNP strain. Comprising the following steps: on the basis of a salmonella VNP20009 strain, flagellin genes fliC and fljB, a phosphoethanolamine transferase gene eptA, a 4-amino-4-deoxy-L-arabinose transferase gene arnT and phosphotransferase yeiU are sequentially knocked out or silenced, and a strain is formed after a phosphotransferase gene lpxE is knocked in or overexpressed, so that the attenuated salmonella typhimurium EN-VNP strain is prepared. According to the attenuated salmonella typhimurium EN-VNP with low toxicity and the T cell adjuvant effect and an EN-OMV antigen delivery system prepared from the attenuated salmonella typhimurium EN-VNP, an improved strain does not contain flagellin, an LPS molecular structure is changed, the attenuated salmonella typhimurium EN-VNP has the low toxicity and the T cell adjuvant effect, and normal multiplication culture can be achieved.

A spore of a bacillus subtilis B.subtilis WB600 strain is used as an antigen delivery carrier, spore coat protein C (CotC) is used as anchoring protein, a key protein ATPase gene and a CotC gene of micropterus salmoides iridovirus are fused through a gene fusion technology, a recombinant spore surface display system is constructed, the ATPase antigen is stably displayed on the spore surface, and an oral vaccine is prepared. After being orally applied to fishes, the vaccine can tolerate the gastrointestinal tract environment and is accurately delivered to intestinal related lymphatic tissues to stimulate fish immunity, and finally prevention and control of the iridovirus of the micropterus salmoides are achieved.

The invention relates to a cationized manganese nano adjuvant as well as a preparation method and application thereof. The cationized manganese nano adjuvant comprises manganous-manganic oxide nano particles and cationized template molecules wrapping the surfaces of the manganous-manganic oxide nano particles, the cationization template molecule is a protein subjected to cationization modification treatment, or a protein fragment thereof, or a polypeptide fragment thereof. Precise regulation and control of surface charges and structures of the manganese nanoparticles are realized through a biomineralization technology, and the key problems of a traditional vaccine adjuvant in the aspects of antigen delivery, immune activation and biocompatibility are effectively solved. The cationized manganese nano adjuvant can efficiently adsorb various antigens to form a stable nano vaccine compound, and congenital immunity and adaptive immunity response of an organism can be remarkably activated; lymph nodes can be effectively targeted, the enrichment degree of antigens in the lymph nodes is improved, and the immune effect is further enhanced; meanwhile, the biotoxicity is low, and the stability is excellent.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

The invention provides an allosteric nanogel adjuvant as well as a preparation method and application thereof, and belongs to the technical field of vaccines. The allosteric nanogel adjuvant comprises a self-assembly motif, a responsive site and an immunomodulatory peptide fragment, and the self-assembly motif is composed of 2-5 amino acids; the allosteric nanogel adjuvant has a structure as shown in a formula I, and is named as NTP5 for short; the allosteric nanogel adjuvant is self-assembled into nanoparticles, the nanoparticles are allosteric into a nanofiber structure through responsive broken bonds, nanogel is further formed, and the key problems of a traditional vaccine in the aspects of antigen delivery and immune activation are effectively solved. The nanogel adjuvant can efficiently load various antigens to form a stable nano vaccine, activate an immune microenvironment and provide more means and thoughts for vaccine development.

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

This invention discloses a lipid nanoparticle co-delivery system based on phenolic hydroxyl lipids and a manganese adjuvant. Addressing the shortcomings of traditional HPV therapeutic peptide vaccines—weak immunogenicity, easy degradation and inactivation in vivo, low bioavailability of manganese ion adjuvants making spatiotemporal co-delivery with antigens, and poor encapsulation efficiency and insufficient biosafety of conventional lipid nanocarriers—this invention constructs an integrated nanovaccine delivery system by embedding phenolic hydroxyl functional lipids into a nanocarrier framework, synergistically loading HPV E6 / E7 specific antigen peptides and manganese ion immune adjuvants. This system achieves efficient delivery, immune activation, and anti-tumor efficacy, integrating the functions of efficient antigen delivery, potent immune activation, and precise anti-tumor action. The preparation process is simple and exhibits excellent stability, overcoming the limitations of traditional HPV peptide vaccines with poor efficacy when used alone. It has broad research value and clinical translation prospects in the field of precision immunotherapy for HPV-related cervical cancer, head and neck squamous cell carcinoma, and other malignant tumors.

The present invention relates to a polypeptide comprising a silk polypeptide and an antigen. Further, the present invention relates to an article comprising the polypeptide. Furthermore, the present invention relates to a pharmaceutical composition comprising the article. In addition, the present invention relates to the article or pharmaceutical composition for use as a pharmaceutical, for inducing an immune response and / or for use in a prophylactic and / or therapeutic treatment of a disease.

A modified adenoviral vector, lacking splice acceptor dinucleotides in a region of the vector and having improved expression is provided.

The present invention relates to a conjugate comprising an mRNA of an antigen protein and an mRNA encoding a carrier protein linked to the 5'terminal and the 3 'terminal of the mRNA of the antigen protein, and an vaccination composition and / or a vaccine composition comprising the conjugate, the present invention having an effect of stably increasing the expression of an antigen protein.

This invention relates to an oral nanomedicine antigen delivery system and its construction method and application, belonging to the field of oral nanomaterials technology; the construction method includes the following steps: (1) preparation of OM nanoparticle suspension; (2) preparation of cationic liposome suspension; (3) preparation of cationic liposome suspension loaded with OM / BF; (4) construction of oral nanomedicine antigen delivery system. This invention breaks through multiple barriers in the gastrointestinal tract, improves drug bioavailability, and achieves precise immune tracking through the OVA tumor antigen model, simulating in vivo anti-tumor CTL response, thereby exerting anti-tumor effects synergistically at the cellular, tissue, and immune levels, effectively solving the problems of poor water solubility and low delivery efficiency of the active ingredient bufotoxin in traditional Chinese medicine. At the same time, through macrophage-mediated immune regulation and precise drug release, it improves targeting and treatment efficiency, opening up a new avenue for tumor immunotherapy with oral nanomedicine.

The invention discloses a preparation and delivery strategy of a dendritic cell targeting vaccine. The vaccine delivery platform comprises: a) an antibody having a DC targeting function, which is selected from a targeting antibody of CD205; and b) a carrier antigen which is obtained by fusion expression of the antibody affinity molecule integrated with the non-natural amino acid and the antigen epitope or the antigen epitope splicing protein. According to the present invention, the CD205 antibody is adopted, the antigen epitope fusion protein containing the antibody affinity molecule is prepared through the UAA integration technology, and the fusion protein can be subjected to proximity induction coupling with the CD205 antibody through the UAA affinity molecule so as to achieve the efficient self-assembly of the CD205 and the antigen epitope; the vaccine delivery platform provided by the invention can realize accurate, efficient and switchable antigen delivery, provides a simple, convenient and flexible DC vaccine design strategy suitable for different antigens, and has a wide immunotherapy application prospect.

The application discloses a kind of based on HIV envelope protein chimeric exosome and its preparation method and application, belong to biological medicine technical field.The application first constructs the cell line of stable expression HIV envelope protein Env, obtains engineered exosome from cell culture supernatant separation and purification;The exosome is used as immunogen combined with adjuvant immunization experimental animal, and high-efficiency induction specific humoral immune response;Again, obtain Env antigen specificity single B cell by flow cytometry sorting, obtain antibody variable region gene by single cell lysis, reverse transcription and nest PCR amplification, cloning to expression vector and expressing in mammalian cell, finally, HIV specific neutralizing antibody is screened by binding activity, affinity and neutralizing activity;The application is combined with single B cell antibody screening technology by embedding HIV Env antigen in the form of membrane combination in exosome surface, and realizes the synergistic optimization of antigen delivery and antibody screening process.

The present application relates to the technical field of medicine, in particular to a functional nanomaterial based on choline phosphate-cell membrane interaction and application thereof.The present application modifies manganese mineralized black phosphorus nanomaterial by bio-inspired polymer pGluCP adsorption, which retains the excellent biocompatibility and photothermal performance of BP, and at the same time, pGluCP enhances the 'chassis' effect of the material, captures tumor-related antigens, and can simultaneously capture water-soluble antigens and water-insoluble membrane antigens and form pathogen-like micro-nanoparticles, which is helpful for antigen delivery and APC presentation, and provides a feasible tool for capturing non-water-soluble membrane antigens, which is a major challenge.MnBP and pGluCP synergistically act, and can realize the personalized conversion of autologous tumors to vaccine production and delivery.

The invention provides an FcRn-targeted Brucella multi-epitope nano vaccine, which can realize long-term protection, shows continuous immune memory, has high-frequency hair-growing central B cells (GCB), follicular helper T cells (TFH) and central memory T cells (TCM), and ensures long-term immune surveillance; even six months after immunization, the serum IgG titer is still obviously higher than that of a control group; efficient antigen delivery can be achieved, specifically, a chitosan-based nano-particle system is adopted, and antigen protection and intestinal epithelium uptake are enhanced through FcRn targeted ligand modification; the delivery efficiency can be improved by 10 times, and the gastrointestinal mucosal barrier is overcome; in addition, rapid immune starting can be achieved, multi-dimensional immune response is induced within 14 days after final immunization, and rapid protection is provided for resisting brucella infection.

The application discloses an engineered potent dendritic cell vaccine and a preparation method and application thereof, and utilizes a nano-scale antigen delivery mode to fuse tumor antigens with cationic liposomes, destroys the stability of a lysosome membrane by means of cationic liposome charge interaction, makes part of the antigens escape into a cytoplasm to be cross-presented through an MHC I pathway, gives the DCs the ability to activate a cellular immune response to resist tumors, on the other hand, gives the DCs T cell directivity through a synthetic immunology method, promotes the interaction and signal transmission of DC-T cells, and the combination of the two mechanisms can overcome the low response rate problem of the existing DC vaccine, and maximizes the anti-tumor immune response.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

A peptide vaccine composition for reducing the progression of atherosclerosis comprises peptides derived from the E3 region of the TRPM2 ion channel from various species, either alone or in combination. A pharmaceutical formulation comprises the peptide vaccine composition and an adjuvant. By utilizing the TRPM2 peptides, the peptide vaccine composition and pharmaceutical formulation of the present invention are capable of producing effective anti-TRPM2 polyclonal antibodies that can reduce the progression of atherosclerosis in an apoE knockout mouse model. Furthermore, the present invention identifies the most suitable antigen delivery pathway for endogenously producing anti-TRPM2 polyclonal antibodies to alleviate atherosclerosis.

The present application relates to the technical field of tumor immunotherapy. The present application provides a responsive antigen capture nano platform, a preparation method and application thereof. The product of the present application is applied by systemic administration such as intravenous injection; can specifically respond to peroxynitrite in the tumor microenvironment, realize the precise activation of the tumor site; can covalently capture tumor-related antigens through high efficiency, deliver the antigens to antigen presenting cells, so as to enhance the anti-tumor immune response; combined with photodynamic therapy can significantly inhibit tumor growth.

The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, for example, including annexin core domains for mediating effective antigen delivery and antigen presentation to induce antigen-specific immune responses, and / or to treat or prevent infectious diseases and / or cancer.

The invention relates to an oral nano traditional Chinese medicine antigen delivery system as well as a construction method and application thereof, and belongs to the technical field of oral nano materials. The construction method comprises the following steps: (1) preparing an OM nanoparticle suspension; (2) preparing a cationic liposome suspension; (3) preparing an OM / BF loaded cationic liposome suspension; and (4) constructing an oral nano traditional Chinese medicine antigen delivery system. According to the invention, multiple barriers of gastrointestinal tracts are broken through, the bioavailability of drugs is improved, precise immune tracking is realized through an OVA tumor antigen model, and in-vivo anti-tumor CTL reaction is simulated, so that an anti-tumor effect is synergistically exerted on three levels of a cell level, a tissue level and an immune level; according to the preparation method, the problems of poor water solubility and low delivery efficiency of bufalin serving as a traditional Chinese medicine active ingredient are effectively solved, meanwhile, through macrophage-mediated immunoregulation and accurate drug release, the targeting property and the treatment efficiency are improved, and a new way is opened up for tumor immunotherapy of oral nano traditional Chinese medicines.

Developing an effective HIV-1 vaccine is contingent on generating protective antibodies (Abs). Novel antigen delivery methods are needed to enhance immune responses. One promising approach involves directing antigens to dendritic cells (DC) through fused monoclonal antibodies (mAbs) to amplify both cellular and humoral responses. Here, the inventors aimed to refine Langerhans cells (EC) targeting by designing three Env monochains instead of 2 (EC3. Env3) mimicking natural Env conformation. The inventors demonstrated that EC3. Env3 construct (i) elicited a rapid and potent Env-IgG response, (ii) enhanced the avidity of anti-Env IgG that was accompanied by a marked expansion of Tfh and GC B cells and (iii) swiftly induced the formation of structured germinal centers in dLN, indicative of a robust immune response. Finally, significant Tier-1 NeutAb induction was observed in rabbits immunized with the construct. In conclusion, HIV Env antigen can be adaptively targeted to LC as a timer, intensifying both the magnitude and quality of humoral responses. The present invention thus relates to the use of such a construct as LC targeting HIV-1 vaccines.

In one aspect, the disclosure relates to recombinant bacterial vectors including a gene encoding at least one antigen from Aeromonas hydrophila or tilapia lake virus, methods of making the same, vaccines incorporating the same, and methods of inducing an immune response in the subject and / or preventing infection by a pathogen in the subject using the same. In one aspect, the subject is a fish in an aquaculture system. In an aspect, the vector or vaccine can be administered by bath immersion or intracoelomic injection and, in some cases, can confer protection against an additional pathogen such as, for example, Edwardsiella piscicida. In any of these aspects, the vectors are susceptible to antibiotics and do not persist in the environment.

The invention provides a microbial carrier vaccine, a preparation method thereof and a vaccine composition. A microbial carrier vaccine for antigen delivery with an enteric microbial delivery system is provided, and the enteric microbial delivery system is selected from at least one of a bacteriophage delivery system (e.g., Klebsiella pneumoniae bacteriophage), an Escherichia coli delivery system (e.g., Klebsiella pneumoniae bacteriophage), and an antigen delivery system (e.g., Klebsiella pneumoniae bacteriophage). Escherichia coli S17-1 lambda pi) or a conjugation delivery system of Escherichia coli and intestinal symbiotic bacteria. The microbial carrier vaccine is a vaccine platform developed based on intestinal microorganisms, after the vaccine enters a body, intestinal symbiotic bacteria can be subjected to in-situ editing, so that the intestinal symbiotic bacteria can continuously generate antigens to be applied to the body, the body can be continuously stimulated to generate antibodies, and the continuous protection effect is achieved.

The invention discloses an application of nano-selenium biological particles as a protein vaccine carrier or preparation of an antibacterial infection drug or an antioxidant drug, and belongs to the technical field of vaccine delivery carriers. The invention aims to provide a novel microbial particle which is used as an anti-infection and anti-oxidation drug, can induce training immunity, and has multiple functions of antibiosis, anti-infection, anti-oxidation and antigen delivery. The invention provides an application of a nano-selenium biological particle as a protein vaccine carrier, or preparation of a bacterial-like particle for preventing bacterial infection, or an application of the nano-selenium biological particle as an antioxidant drug. In-vitro RAW264.7 cells and in-vivo mouse peritoneal macrophages are induced to generate a training immunophenotype, and the vaccine can be used as a vaccine delivery vector to be connected with a staphylococcus aureus mode antigen to design a novel multifunctional biological material by utilizing training immunity to resist multi-drug-resistant bacterium infection, which is a novel strategy.

The present invention relates to a fusion protein comprising a peptide antigen containing a T cell epitope, a first carrier protein linked to the N-terminus of the peptide antigen, and a second carrier protein linked to the C-terminus of the peptide antigen; a nucleic acid molecule encoding the fusion protein; an expression vector containing the nucleic acid molecule; a cell transformed with the expression vector; and an immunogenic composition comprising the fusion protein, the nucleic acid molecule, the expression vector, or the cell.

Because of its myeloid-specific expression, it was hypothesized that CD200R could provide both an inhibitory signal and a target for antigen delivery to antigen presenting cells if antigens are fused recombinantly to a soluble CD200. The examples demonstrate that immunological tolerance can be established using antigen-fused CD200 molecules, including CD200Fc- fused antigen. This tolerance was demonstrated by abrogating responses to immune challenge and induction of production of tolerogenic cytokines, including IL- 10. Accordingly, the polypeptides, compositions, and methods are useful for tolerization of any antigen, such as any antigen related to autoimmune conditions, allergy conditions, anti-drug immunity conditions, among others. Described here is a polypeptide comprising a CD200 polypeptide operatively linked to an antigen. Also provided is a nucleic acid encoding a polypeptide, an expression vector comprising a nucleic acid of the disclosure, host cells comprising a polypeptide of the disclosure. Also described are methods utilizing the polypeptides and compositions.

The invention discloses a recombinant expression vector as well as a construction method and application thereof. The invention also discloses a recombinant strain as well as a construction method and application thereof. The invention also discloses a genetic engineering live vector vaccine. According to the invention, probiotic bacillus subtilis is used as an antigen delivery carrier, and recombinant bacillus subtilis for recombinant integration tandem expression of porcine epidemic diarrhea virus antigen neutralizing epitopes and intestinal M cell and dendritic cell (DCs) targeting peptides is constructed. The recombinant live vector vaccine is orally taken and immunized by sows, and efficient intestinal mucosa immune protection is provided for piglets in the lactation period by enhancing the intestinal mammary axial function of the sows, so that a safe, simple and convenient immune way is provided for effectively preventing the occurrence of epidemic diarrhea of the piglets.

The present invention relates to a fusion protein comprising a peptide antigen and a human thioredoxin linked to the N-terminus, C-terminus or both ends of the peptide antigen wherein all cysteine residues in the amino acid sequence of the human thioredoxin are replaced with non-cysteine residues; the invention also relates to a nucleic acid molecule encoding the fusion protein, an expression vector comprising the nucleic acid molecule, a cell transformed with the expression vector, and a composition comprising the fusion protein, the nucleic acid molecule, the expression vector or the cell.

The invention discloses a preparation method and application of a vesicle vaccine based on a chitosan antigen delivery system, the vesicle vaccine stimulates cells to secrete the vesicle vaccine with an antigen presentation function, and the method related to the system specifically comprises the following steps: step 1, mixing antigen protein with a chitosan aqueous solution and a sodium tripolyphosphate aqueous solution, and carrying out electrostatic interaction to obtain a vesicle vaccine solution; chitosan nanoparticles loaded with the antigen protein are prepared; and 2, treating immune cells by using the antigen-loaded chitosan nanoparticles, collecting cell culture supernatant, and collecting and preparing vesicles by adopting a method of combining multi-step differential centrifugation with ultrafiltration. After the antigen delivery system based on chitosan is co-incubated with cells, antigen protein can be effectively delivered into immune cells, meanwhile, the immune cells are promoted to generate a large number of antigen-related vesicles with efficient immunogenicity through the adjuvant effect and autophagy regulation effect of chitosan, and the immunogenicity of the antigen-related vesicles is improved. The application potential of the artificial antigen presenting cell is realized.